Beta Bionics, Inc. (BBNX) Stock Statistics & Valuation Metrics

Beta Bionics, Inc. has a market cap or net worth of ―. The enterprise value is $102.98M.

Beta Bionics, Inc. has 43,356,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Beta Bionics, Inc.’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -34.80%.

The current PE Ratio of Beta Bionics, Inc. is -2.75. Beta Bionics, Inc.’s PEG ratio is 0.08.

In the last 12 months, Beta Bionics, Inc. had revenue of 65.12M and earned -54.76M in profits. Earnings per share was -8.60.

In the last 12 months, operating cash flow was -34.25M and capital expenditures -894.00K, giving a free cash flow of -35.15M billion.

Beta Bionics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Beta Bionics, Inc. upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.

Beta Bionics, Inc. as a current ratio of 6.29, with Debt / Equity ratio of 7.21%

In the past 12 months, Beta Bionics, Inc. has paid 0.00 in taxes.

Beta Bionics, Inc. EV to EBITDA ratio is -2.89, with an EV/FCF ratio of -2.46.

Beta Bionics, Inc. has $231.47M in cash and marketable securities with $6.97M in debt, giving a net cash position of -$224.50M billion.

Gross margin is 52.59%, with operating margin of -69.48%, and net profit margin of -84.08%.

The average price target for Beta Bionics, Inc. is $26.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy